共查询到20条相似文献,搜索用时 93 毫秒
1.
HSP70和Survivin在骨肉瘤中的表达及其临床意义 总被引:4,自引:0,他引:4
目的 探讨骨肉瘤组织中HSF70和Survivin的表达及其临床意义。方法 应用免疫组化方法检测34例骨肉瘤病人的骨肉瘤组织和15例正常骨组织中HSF70和Survivin的表达情况,综合分析临床病理指标。结果34例骨肉瘤组织中HSF70和Survivin的阳性表达率分别为88.2%和82.4%,而正常骨组织其表达率均为零。HSF70和Survivin在低分化组和短生存组的骨肉瘤中,其阳性表达率明显高于高、中分化组和长生存组骨肉瘤。结论 检测HSF70和Survivin为骨肉瘤恶性程度和预后的评估提供了一定的辅助参考指标。 相似文献
2.
3.
目的 :研究 HSP70复合物抗人肝癌细胞的免疫效应。方法 :用经 42℃热休克处理的 SMMC- 772 1细胞制备裂解液 ,免疫共沉淀法提取 HPS70复合物 ,采用 SDS- PAGE和 Western- blot鉴定蛋白性质及分子量 ;蛋白测定仪进行复合物定量。 MTT法检测 HSP70复合物体外致敏人脾淋巴细胞对 SMMC- 772 1的细胞毒作用。结果 :SDS- PAGE和 Western- blot证实获得相对分子量约为 7× 10 4的 HSP70蛋白 ;体外细胞毒实施显示在不同效靶比时 ,致敏的淋巴细胞对 SMMC- 772 1均具有一定的杀伤效应 ,且这种效应可被 CD4、CD8的单抗部分阻断。结论 :HSP70复合物能在体外诱导针对人肝癌细胞的淋巴细胞毒效应 ,CD4、CD8介导了部分抗瘤作用 ,提示 HSP70可能通过多种免疫途径参与抗瘤效应。HSP70复合物抗人肝癌免疫的初步研究为今后临床肝癌瘤苗的研制和生物治疗奠定了良好的基础 相似文献
4.
5.
目的探讨热休克蛋白(HSP70)与胆囊癌的发生及发展的关系。方法用免疫组化S
P法检测45例胆囊癌中热休克蛋白的表达情况,并与41例慢性胆囊炎标本做对照。结果热休克蛋白(HSP70)在胆囊癌中普遍呈现高表达,而在慢性胆囊炎组织中不同程度地呈现弱表达;HSP70在胆囊癌组织中的表达明显高于慢性胆囊炎组(P〈0.01),且强阳性表达高于后者(P〈0.01)。结论胆囊癌是HSP70高表达肿瘤,HSP70在原发性胆囊癌中普遍高表达,提示与胆囊癌的发生发展有关。 相似文献
6.
目的:探讨细胞外热休克蛋白70(heatshock protein 70。HSP70)的释放、功能、免疫学机制以及在肿瘤免疫治疗中的应用。方法:应用Medline、PubMed及CNKI期刊全文数据库检索系统.以“细胞外热休克蛋白70的释放、肿瘤免疫、应用”为关键词,检索2002—2013年的相关文献。纳入标准:1)细胞外热休克蛋白的功能;2)细胞外热休克蛋白的释放机制;3)细胞外热休克蛋白与肿瘤免疫。根据纳入标准符合分析的文献28篇。结果:HSP70不仅在细胞内发挥重要的作用,还可以通过其特有机制释放到细胞外。细胞外HSP70有重要的生物学功能.存在于细胞外的HSP70能够发挥抗肿瘤免疫作用。应用细胞外HSP70/HSP70-PCs制成特异性抗肿瘤疫苗,为肿瘤的治疗提供新的思路。结论:细胞外HSP70的肿瘤免疫作用及在肿瘤疫苗方面的应用,将有望成为肿瘤治疗的新方法。 相似文献
7.
榄香烯复合瘤苗对Hca-F肝癌小鼠的免疫治疗效应及对IL-10与IL-12分泌的影响 总被引:7,自引:0,他引:7
目的探讨榄香烯复合瘤苗(EC-TCV)对小鼠肝癌Hca-F的免疫治疗效应及治疗小鼠脾细胞IL-10与IL-12分泌的变化。方法带Hca-F小鼠分别用EC-TCV,CY,EC-TCV+CY治疗或不治疗(PBS对照),观察比较肿瘤生长情况并用ELISA法测脾细胞与Hca-F细胞混合培养上清中的IL-10与IL-12。结果EC-TCV免疫治疗或CY化疗后,肿瘤潜伏期延长,瘤重减轻,用EC-TCV+CY进行化免治疗的小鼠在第15天活杀时均无瘤生长,与Hca-F细胞混合培养的EC-TCV治疗小鼠脾细胞培养上清中IL-10浓度明显降低(1.82±0.29pg/ml,P<0.05),IL-12浓度明显升高(7.13±1.89pg/ml,P<0.05)。结论EC-TCV对Hca-F有免疫治疗效应,可与CY并用而加强,而EC-TCV主动免疫促进脾细胞IL-12分泌、抑制IL-10分泌可能是其抗瘤作用的机制之一。 相似文献
8.
9.
目的 研究用来自亚高温盆腔区域热疗后原位大鼠膀胱肿瘤的热休克蛋白70-肽复合物(HSP70-PC)对原位大鼠膀胱肿瘤的治疗作用机制。方法 经尿道膀胱灌注MNU制备出大鼠膀胱肿瘤动物模型。将动物随机分为A(肿瘤对照)组、B(HSP70-PC治疗)组、C(肿瘤细胞裂解液治疗)组,每组5只。皮下注射治疗1个月后检测膀胱及肿瘤湿重,肿瘤分期分级,TUNEL法检测肿瘤细胞凋亡指数(AI),免疫组化检测肿瘤细胞增殖细胞核抗原指数(PCNA LI)、肿瘤组织中S-100蛋白阳性细胞率及CD8阳性细胞率、膀胱引流区域髂动脉及腹主动脉旁淋巴结中S-100蛋白阳性细胞率、脾脏S-100蛋白阳性细胞率及CD8阳性细胞率,ELISA法检测血清Rat IFN-γ含量。结果 膀胱及肿瘤湿重B组低于A、C组(P<0.01)。A、C组间差异无显著性意义(P = 0.610)。B组肿瘤分期低于A、C组(P<0.01);A、C组间差异无显著性意义(P =1.00)。肿瘤分级各组间差异均无显著性意义(P =1.00)。B组肿瘤细胞AI、膀胱肿瘤组织中CD8阳性细胞率、血清Rat IFN-γ含量均高于A、C组(P<0.01);A、C组间差异均无显著性意义(P =0.870,0.597,0.979)。脾脏S-100蛋白阳性细胞率及CD8阳性细胞率由高到低依次为B、C、A组(P<0.01)。肿瘤细胞PCNA LI、膀胱肿瘤组织中S-100蛋白阳性细胞率、淋巴结中S-100蛋白阳性细胞率三组之间差异均无显著性意义(P =0.808,0.718,0.847)。结论 皮下注射HSP70-PC可以上调原位的膀胱肿瘤大鼠的细胞免疫状态,促进肿瘤凋亡,但对肿瘤细胞增生无影响。 相似文献
10.
11.
树突状细胞肿瘤免疫治疗临床应用进展 总被引:5,自引:1,他引:5
树突状细胞由于能够刺激并致敏初始T细胞和启动早期免疫反应而被公认为是最具潜能的抗原提呈细胞。树突状细胞疫苗的抗肿瘤免疫治疗效果在动物模型中得到了验证 ,同时人树突状细胞培养的方法也得到了进一步的改进和完善。因而 ,树突状细胞疫苗的抗肿瘤免疫治疗得以进入Ⅰ~Ⅱ期临床研究。本文就近年来应用树突状细胞疫苗进行抗肿瘤免疫治疗的临床研究中 ,树突状细胞的获取和培养、树突状细胞的输注途径和剂量、目前临床应用治疗的肿瘤类型和方法以及治疗的疗效及评价指标进行了综述。 相似文献
12.
Synat Kang Xuefeng Gao Li Zhang Erna Yang Yonghui Li Li Yu 《Current oncology (Toronto, Ont.)》2021,28(2):1077
Natural killer (NK) cells can be widely applied for cancer immunotherapy due to their ability to lyse tumor targets without prior sensitization or human leukocyte antigens-matching. Several NK-based therapeutic approaches have been attempted in clinical practice, but their efficacy is not sufficient to suppress tumor development mainly because of lacking specificity. To this end, the engineering of NK cells with T cell receptor along with CD3 subunits (TCR-NK) has been developed to increase the reactivity and recognition specificity of NK cells toward tumor cells. Here, we review recent advances in redirecting NK cells for cancer immunotherapy and discuss the major challenges and future explorations for their clinical applications. 相似文献
13.
Dr Michael A. Morse Paul J. Mosca Timothy M. Clay H. Kim Lyerly 《American Journal of Cancer》2002,1(5):313-322
Therapeutic vaccines that can activate the immune system to destroy malignancies hold the promise of a low-toxicity, precisely targeted anticancer treatment modality. Because dendritic cells (DCs) are central to the activation of antigen-specific immune responses, DCs loaded with tumor antigens are of considerable interest as therapeutic vaccines. Preclinical studies have demonstrated the potency of DC-based immunizations in promoting tumor rejection. Continued preclinical and clinical studies are assessing a number of important parameters regarding the formulation and administration regimen of DC-based vaccines and have provided support for phase I and II studies. Thus far, DC-mediated immunizations have been well tolerated, with few toxicities reported. Tumor regression has been reported in up to 30% of patients, particularly with immunologically sensitive tumors such as melanoma. Biologic activity, measured as activation of antigen-specific T cells, is reported in up to 100% of patients immunized against potent recall antigens, such as tetanus toxoid, and up to 30% of those immunized against tumor antigens. Current clinical trials are increasingly testing DC-based vaccines in patients with minimal residual disease, such as following attempted curative surgery or following high-dose chemotherapy and stem-cell support where clinical benefit is likely to be the greatest. Newer strategies are focusing on further modifications to DCs to increase their immuno stimulatory potency. These include newer methods of antigen loading, better techniques for DC maturation, strategies to enhance polarization of DCs to ensure the induction of T helper cell type 1 immune responses, and the administration of adjunctive cytokines to augment the immune response following immunization. 相似文献
14.
15.
16.
目的: 使用以毕赤酵母X-33为宿主菌,重组表达制备的rhHSP70与合成的HER2/neu抗原肽体外结合形成复合物,探讨其在肿瘤免疫治疗中的有效性。 方法: 在ADP存在的条件下,将rhHSP70与纯化的HER2/neu抗原肽体外非共价结合形成复合物,并分次免疫BALB/c小鼠,通过ELISPOT和颗粒酶释放法,检测该复合物诱导特异性CTL的能力。通过检测小鼠体内肿瘤的生长情况和肿瘤的组织切片,来观测该复合物对小鼠乳腺癌的免疫治疗作用。 结果: rhHSP70-HER2/neu抗原肽复合物免疫小鼠后,可以增加T细胞分泌IFN-γ的能力,诱导出肿瘤特异性CTL,并对小鼠的乳腺癌有明显的治疗作用。 结论: 在毕赤酵母中重组表达的rhHSP70可以在体外与一定的抗原肽非共价结合形成复合物,该复合物具有较强的诱导特异性CTL的能力,可对实验鼠的乳腺癌起到明显的治疗作用。 相似文献
17.
18.
Breast irradiation has long been utilized in the adjuvant or metastatic setting to eliminate microscopic disease or to palliate existing disease, respectively. However, preclinical data have demonstrated that radiation can also alter the tumor microenvironment and induce antitumor immune responses. As a result, multiple clinical studies have been undertaken and have reported synergy between radiation and immune checkpoint blockade across various cancer types. Given recent clinical successes with immune checkpoint blockade in both early-stage and metastatic breast cancer, there has been substantial interest in combining radiation and immunotherapy to enhance local and systemic immune responses. Herein, we review the preclinical rationale for combining radiotherapy and immunotherapy, the early clinical trials that have adopted this strategy in breast cancer, and the landscape of ongoing relevant clinical trials. Finally, we propose future directions based on promising preclinical studies that integrate radiation, checkpoint blockade, and novel agents for the treatment of breast cancer. 相似文献
19.